12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)

Condition:   Breast Cancer Interventions:   Drug: Trastuzumab;   Drug: Docetaxel Sponsor:   Ruijin Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials